Acumen Pharmaceuticals (NASDAQ:ABOS) is a biopharmaceutical company focused on developing novel therapies for the treatment of Alzheimer's disease and related neurodegenerative conditions. Acumen's primary project revolves around targeting and neutralizing amyloid-beta oligomers, which are thought to play a key role in the progression of Alzheimer's disease. The objective of the company is to advance its lead candidate through clinical trials to address the urgent need for effective treatments against Alzheimer's, aiming to improve the quality of life for patients and their families affected by this devastating condition. Acumen Pharmaceuticals is dedicated to pushing the boundaries of neuroscience and biotechnology to bring innovative solutions to the forefront of healthcare.